Turning Point Therapeutics (NASDAQ: TPTX)
Some price data may be temporarily unavailable.
Turning Point Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Turning Point Therapeutics Company Info
Turning Point Therapeutics is a clinical-stage structure-based drug design company for the discovery and development of precision medicines for cancer and other diseases. They focus on the design of novel chemical identities for established oncogene drivers with secondary resistant mutations, newly identified disease-driven targets, and potential targets regulating the tumor microenvironment and tumor immunity.
News & Analysis
Why Turning Point Is Turning Heads
This oncology biotech is up over 450% since its April 2019 IPO. Are there still gains to come, or should investors turn away?
Turning Point Therapeutics Licenses Its Lung Cancer Drug in China
Zai Labs will pay up to $176 million for the rights to sell repotrectinib in the Greater China market.
These Were the 10 Best IPOs of 2019
Incredibly, they're almost all health stocks, including 7 biotechs, an eye surgery platform, and a medical device company.
Are There Good Investments Among 2019's Biotech IPOs?
Investing in biotechs is inherently risky. IPOs are too. What does the stock performance of 2019’s biotech IPO class look like so far?
Valuation
Earnings Transcripts
Turning Point Therapeutics Inc (TPTX) Q1 2020 Earnings Call Transcript
TPTX earnings call for the period ending March 31, 2020.
Turning Point Therapeutics Inc (TPTX) Q3 2019 Earnings Call Transcript
TPTX earnings call for the period ending September 30, 2019.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.